A detailed history of Capital Advisors Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Capital Advisors Inc holds 344,314 shares of ABBV stock, worth $59.1 Million. This represents 1.36% of its overall portfolio holdings.

Number of Shares
344,314
Previous 408,543 15.72%
Holding current value
$59.1 Million
Previous $63.3 Million 0.97%
% of portfolio
1.36%
Previous 1.43%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$159.82 - $182.1 $10.3 Million - $11.7 Million
-64,229 Reduced 15.72%
344,314 $62.7 Million
Q4 2023

Jan 29, 2024

BUY
$137.6 - $154.97 $4.25 Million - $4.79 Million
30,898 Added 8.18%
408,543 $63.3 Million
Q3 2023

Oct 24, 2023

BUY
$133.59 - $154.65 $1.06 Million - $1.23 Million
7,924 Added 2.14%
377,645 $56.3 Million
Q2 2023

Jul 18, 2023

BUY
$132.51 - $164.9 $2.9 Million - $3.61 Million
21,876 Added 6.29%
369,721 $49.8 Million
Q1 2023

Apr 19, 2023

BUY
$144.61 - $166.54 $641,489 - $738,771
4,436 Added 1.29%
347,845 $55.4 Million
Q4 2022

Jan 17, 2023

BUY
$138.31 - $165.87 $113,967 - $136,676
824 Added 0.24%
343,409 $0
Q3 2022

Oct 17, 2022

BUY
$134.21 - $153.93 $1.23 Million - $1.41 Million
9,130 Added 2.74%
342,585 $46 Million
Q2 2022

Jul 15, 2022

BUY
$137.62 - $174.96 $783,333 - $995,872
5,692 Added 1.74%
333,455 $51.1 Million
Q1 2022

May 05, 2022

BUY
$131.98 - $163.75 $581,899 - $721,973
4,409 Added 1.36%
327,763 $53.1 Million
Q4 2021

Jan 27, 2022

BUY
$107.43 - $135.93 $48,665 - $61,576
453 Added 0.14%
323,354 $43.8 Million
Q3 2021

Oct 25, 2021

BUY
$106.4 - $120.78 $115,550 - $131,167
1,086 Added 0.34%
322,901 $34.8 Million
Q2 2021

Aug 02, 2021

BUY
$105.21 - $117.21 $787,286 - $877,082
7,483 Added 2.38%
321,815 $36.2 Million
Q1 2021

May 25, 2021

BUY
$102.3 - $112.62 $1.02 Million - $1.12 Million
9,925 Added 3.26%
314,332 $34 Million
Q4 2020

Feb 08, 2021

BUY
$80.49 - $108.67 $732,861 - $989,440
9,105 Added 3.08%
304,407 $32.6 Million
Q3 2020

Nov 02, 2020

BUY
$85.91 - $100.83 $381,612 - $447,886
4,442 Added 1.53%
295,302 $25.9 Million
Q2 2020

Aug 07, 2020

BUY
$73.37 - $98.18 $397,005 - $531,251
5,411 Added 1.9%
290,860 $26.9 Million
Q1 2020

May 21, 2020

BUY
$64.5 - $97.79 $16.6 Million - $25.2 Million
257,210 Added 910.83%
285,449 $21.7 Million
Q4 2019

Feb 04, 2020

BUY
$72.13 - $90.25 $26,615 - $33,302
369 Added 1.32%
28,239 $2.5 Million
Q2 2019

Aug 07, 2019

BUY
$65.7 - $83.98 $1.83 Million - $2.34 Million
27,870 New
27,870 $0
Q1 2019

May 10, 2019

SELL
$77.14 - $90.79 $2.25 Million - $2.65 Million
-29,139 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$77.85 - $96.01 $99,570 - $122,796
1,279 Added 4.59%
29,139 $2.69 Million
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $11,113 - $12,355
125 Added 0.45%
27,860 $2.64 Million
Q2 2018

Aug 06, 2018

SELL
$89.78 - $106.23 $6,733 - $7,967
-75 Reduced 0.27%
27,735 $0
Q1 2018

May 04, 2018

SELL
$92.01 - $123.21 $136,634 - $182,966
-1,485 Reduced 5.07%
27,810 $0
Q4 2017

Jan 29, 2018

BUY
$89.56 - $98.21 $124,667 - $136,708
1,392 Added 4.99%
29,295 $2.83 Million
Q3 2017

Nov 14, 2017

SELL
$69.85 - $89.22 $179,514 - $229,295
-2,570 Reduced 8.43%
27,903 $2.48 Million
Q2 2017

Aug 09, 2017

BUY
N/A
30,473
30,473 $2.21 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Capital Advisors Inc Portfolio

Follow Capital Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Capital Advisors Inc with notifications on news.